Literature DB >> 10573511

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

P Angulo1, J C Keach, K P Batts, K D Lindor.   

Abstract

Nonalcoholic steatohepatitis (NASH) may present with increased hepatic fibrosis progressing to end-stage liver disease. No factors that determine increasing fibrosis and histologically advanced disease have been recognized, thus, liver biopsy is recommended in all patients for diagnosis and prognosis. Our aim was to identify independent predictors of severe hepatic fibrosis in patients with NASH. One hundred and forty-four patients were studied. All patients underwent liver biopsy. Clinical and biochemical variables were examined with univariate and multivariate analysis. Thirty-seven (26%) patients had no abnormal fibrosis, 53 (37%) had mild fibrosis, 15 (10%) had moderate fibrosis, 14 (10%) had bridging fibrosis, and 25 (17%) had cirrhosis. In multivariate analysis, older age (P =. 001), obesity (P =.002), diabetes mellitus (P =.009), and aspartate transaminase/alanine transaminase (AST/ALT) ratio greater than 1 (P =.03) were significant predictors of severe liver fibrosis (bridging/cirrhosis). Body mass index (P =.003) was the only independent predictor of the degree of fat infiltration. Increased transferrin saturation correlated positively with the severity of fibrosis (P =.02) in univariate analysis, and there was a trend for more female patients among those with more advanced fibrosis (P =. 09). However, iron studies or gender were not significant when controlled for age, obesity, diabetes, and AST/ALT ratio. In conclusion, older age, obesity, and presence of diabetes mellitus help identify those NASH patients who might have severe liver fibrosis. This is the subgroup of patients with NASH who would be expected to derive the most benefit from having a liver biopsy and considering investigational therapies.

Entities:  

Mesh:

Year:  1999        PMID: 10573511     DOI: 10.1002/hep.510300604

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  404 in total

1.  Structure of the pentapeptide proctolin, a proposed neurotransmitter in insects.

Authors:  A N Starratt; B E Brown
Journal:  Life Sci       Date:  1975-10-15       Impact factor: 5.037

2.  Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey.

Authors:  Lei Shen; Jian-Gao Fan; Yan Shao; Min-De Zeng; Jun-Rong Wang; Guo-Hao Luo; Ji-Qiang Li; Si-Yao Chen
Journal:  World J Gastroenterol       Date:  2003-05       Impact factor: 5.742

Review 3.  Mallory-Denk Bodies in chronic hepatitis.

Authors:  Metin Basaranoglu; Nesrin Turhan; Abdullah Sonsuz; Gökcen Basaranoglu
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

4.  To perform or not to perform liver biopsy: an alternative view.

Authors:  R W Chapman
Journal:  Gut       Date:  2003-08       Impact factor: 23.059

Review 5.  Non-alcoholic fatty liver disease: a diabetologist's perspective.

Authors:  Joseph M Pappachan; Farrah A Antonio; Mahamood Edavalath; Arjun Mukherjee
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

Review 6.  Hepatic steatosis and type 2 diabetes mellitus.

Authors:  Jeanne M Clark; Anna Mae Diehl
Journal:  Curr Diab Rep       Date:  2002-06       Impact factor: 4.810

7.  Effects of amlodipine, captopril, and bezafibrate on oxidative milieu in rats with fatty liver.

Authors:  Zvi Ackerman; Mor Oron-Herman; Talma Rosenthal; Orit Pappo; Gabriela Link; Ben-Ami Sela; Maria Grozovski
Journal:  Dig Dis Sci       Date:  2007-08-22       Impact factor: 3.199

Review 8.  Non-alcoholic fatty liver disease: an emerging pathological spectrum.

Authors:  Elie Serge Zafrani
Journal:  Virchows Arch       Date:  2003-12-18       Impact factor: 4.064

9.  Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma.

Authors:  Hiroshi Abe; Yuta Aida; Haruya Ishiguro; Kai Yoshizawa; Tamihiro Miyazaki; Munenori Itagaki; Satoshi Sutoh; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 10.  Nonalcoholic fatty liver disease: current issues and novel treatment approaches.

Authors:  Romina Lomonaco; Nishanth E Sunny; Fernando Bril; Kenneth Cusi
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.